Duvelisib

Drug Profile

Duvelisib

Alternative Names: ABBV-954; INK-1197; IPI-145

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellikine
  • Developer AbbVie; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Verastem
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Nonsteroidal anti-inflammatories; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase I Haematological malignancies; Lymphoma; T cell lymphoma
  • Preclinical Solid tumours
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 06 Sep 2017 Duvelisib receives fast track status for Peripheral T-cell lymphoma in the US
  • 06 Sep 2017 Efficacy data from a phase I trial in Peripheral T-cell lymphoma released by Veristem
  • 06 Sep 2017 Verastem plans an open-label phase II trial for relapsed or refractory Peripheral T-cell lymphoma in December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top